About ONIVYDE
ONIVYDE is a Healthcare company based in Wrexham (United Kingdom) founded in 2013, and was acquired by Ipsen in January 2017. Information on liposome injections for pancreatic cancer is provided. Its focus areas include Pharmaceutical Product Websites.
Company details
ONIVYDE was founded in 2013 and is based in Wrexham, United Kingdom. Operations are conducted within the pharmaceutical sector, with a focus on oncology. Liposome injections targeted at pancreatic cancer treatment are developed, and related information is made available through the domain onivyde.com. Activities encompass research, formulation, and dissemination of data on these therapies, supporting clinical applications in the United Kingdom and potentially broader markets.
- Headquarters Wrexham, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website onivyde.com/en-us/hcp
- Social Facebook
- Acquired by Ipsen (Jan 2017)
Investors in ONIVYDE
ONIVYDE has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ipsen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | 1929 | ipsen.com |
Investor details for ONIVYDE
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ONIVYDE
2 dated milestones of ONIVYDE across 4 years, from founding to its latest funding, stage changes and deals.
- Founded ONIVYDE is founded.
- Exit Acquired by Ipsen.
Web traffic of ONIVYDE
The website of ONIVYDE (onivyde.com) receives about 5.9K visits a month and ranks #2,890,920 among all websites worldwide, #3,872 in Biotechnology and Pharmaceuticals.
- Monthly visits5.9K
▼ 22.2% vs previous month
- Unique visitors3.7K
per month
- Global rank#2,890,920
among all websites
- Category rank#3,872
Health · Biotechnology and Pharmaceuticals
- Bounce rate61%
- Pages per visit1.5
- Average visit55 sec
- DevicesDesktop 24% · Mobile 76%
Websites whose visitors overlap most with ONIVYDE. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicaltrialsarena.com | 100% | #257,942 | View details | ||
pancreatica.org | pancreatica.org | 74% | #4,936,844 | – | |
| cancer.org | 66% | 2.8M | #23,799 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ONIVYDE
ONIVYDE was founded in 2013.
ONIVYDE is headquartered in Wrexham, United Kingdom. It is registered at Wrexham, Wales, United Kingdom.
ONIVYDE was founded in 2013 and is based in Wrexham, United Kingdom. Operations are conducted within the pharmaceutical sector, with a focus on oncology. Liposome injections targeted at pancreatic cancer treatment are developed, and related information is made available through the domain onivyde.com. Activities encompass research, formulation, and dissemination of data on these therapies, supporting clinical applications in the United Kingdom and potentially broader markets.
ONIVYDE has 1 investor. Key investors include Ipsen.
Yes. ONIVYDE was acquired by Ipsen in January 2017.